# Novavax Plunges 12% as Selloff Hits Vaccine Makers

> Vaccine stocks crash as Novavax drops 12% amid partner Sanofi's rollout.
- Title: Novavax Plunges 12% as Selloff Hits Vaccine Makers | Shortify
- Summary: Vaccine stocks crash as Novavax drops 12% amid partner Sanofi's rollout. Novavax stock fell 12% to $11.23 after Sanofi's Nuvaxovid rollout began in UK…
- Keywords: novavax, sanofi, moderna, pfe, nvax, nasdaq, nvaxovid, citi, vaccine, stock, selloff, royalties
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/10/16/novavax-plunges-12-as-selloff-hits-vaccine-makers-moderna-tumbles-10-pfizer-holds-steady
- Author: David Moadel
- Published: 2026-10-16T16:44:10+00:00
- Read time: 1 min
- Topics: novavax, sanofi, moderna, pfe, nvax, nasdaq, nvaxovid, citi, vaccine, stock, selloff, royalties
## Vaccine Stocks Crashing
Vaccine stocks are under heavy pressure with Novavax dropping 12% to $11.23 in afternoon trading.
## Novavax's Partner Sanofi
Sanofi holds U.S. approval for Novavax's Nuvaxovid vaccine and rolls it out in UK, Germany, and Canada.
## Moderna and Pfizer Tumble
Moderna stock drops 10% to $212.80 while Pfizer holds steady at $29.59.
## Citi's Mixed Signal
Citi keeps Novavax's Sell rating but raises its price target, signaling uncertainty.
## Novavax's Revenue Model
Novavax collects royalties from Sanofi while partners handle manufacturing and sales.
## Sanofi's Rollout Impact
Sanofi's Nuvaxovid rollout in UK, Germany, and Canada affects Novavax's royalty payments.
## Investor Reaction
Investors weigh royalty upside against milestone timing risk for Novavax stock.
## Key takeaway

Novavax stock fell 12% to $11.23 after Sanofi's Nuvaxovid rollout began in UK, Germany, and Canada.